ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2026.05.013
Evaluation of the Efficacy of Camrelizumab Combined with Chemotherapy in the Treatment of Lung Cancer
Haiying Fei
1School of Clinical Medicine, Chengdu Medical College, Chengdu 610500, Sichuan, China.
2Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, Sichuan, China.
3Key Laboratory of Geriatric Respiratory Diseases of Sichuan Higher Education Institutes, Chengdu 610500, Sichuan, China.
*Corresponding author: Haiying Fei
Published: May 25,2026
Abstract
Objective: To explore the efficacy of camrelizumab combined with chemotherapy in the treatment of lung cancer. Methods: A total of 62 lung cancer patients admitted to our hospital from January 2021 to December 2025 who met the research criteria were selected. Using a randomized controlled method, the patients were divided into a study group (n = 31) and a control group (n = 31). The control group received a chemotherapy regimen, while the study group received a camrelizumab combined with a chemotherapy regimen. The clinical effects were compared. Results: The clinical efficacy of the study group was significantly better than that of the control group (87.09% > 64.52%), with P < 0.05, indicating a statistically significant difference. There was no significant difference in the incidence of adverse reactions between the two groups. Relatively speaking, the incidence of adverse reactions in the study group was slightly higher than that in the control group (54.84% > 41.94%), but the difference between the two sets of data was small, with P > 0.05, proving that the incidence of adverse reactions in the study group was controllable and would not significantly increase safety risks, and the difference was not statistically significant. Conclusion: In the treatment of lung cancer, the application of a camrelizumab combined with chemotherapy regimen can improve the treatment effect to a certain extent, enhance the quality of life of patients during the treatment stage as much as possible, ensure patients’ treatment experience and acceptance of various treatment measures, guarantee the smooth implementation of all treatment measures, and effectively improve the safety of patients during the treatment process.
Keywords
Camrelizumab; Chemotherapy; Combined therapy; Lung cancer
References
[1] Wang Y, Fu Q. Clinical efficacy of tislelizumab combined with chemotherapy in the treatment of stage Ⅲb–Ⅳ non‑small cell lung cancer. Clin Rational Drug Use. 2025;18(34):86-88.
DOI:10.15887/j.cnki.13‑1389/r.2025.34.026.
[2] Wang N, Li HB, Sun GJ. Cost‑effectiveness analysis of ivonescablimab combined with chemotherapy in the treatment of EGFR‑mutated advanced non‑small cell lung cancer. Drug Eval Res. 2025;48(12):3699-3706.
[3] Wang Q. Clinical efficacy of immunotherapy combined with bevacizumab and chemotherapy in advanced non‑small cell lung cancer with negative driver genes and non‑squamous type. Smart Health. 2025;11(33):31-34.
DOI:10.19335/j.cnki.2096‑1219.2025.33.009.
[4] Han TR, Xu Y, Wang BS, et al. Meta‑analysis of the efficacy and safety of traditional Chinese medicine adjuvant to camrelizumab combined with chemotherapy in the treatment of non‑small cell lung cancer. Clin Res Tradit Chin Med. 2025;17(31):63-70.
[5] Shi YF, Li YH, Liu S, et al. Cost‑effectiveness analysis of penpulimab combined with chemotherapy as first‑line treatment for metastatic squamous non‑small cell lung cancer based on a partitioned survival model. Eval Anal Drug Use Hosp China. 2025;25(9):1119-1123.
DOI:10.14009/j.issn.1672‑2124.2025.09.019.
[6] Cheng XS, Shen YL, Chen XL. Evaluation of the efficacy of camrelizumab combined with chemotherapy in the treatment of lung cancer. J Shanxi Health Vocat Coll. 2025;35(3):1-3.
DOI:10.20281/j.cnki.wjyxb.000172.
[7] Li W. Efficacy of camrelizumab combined with DDP chemotherapy regimen in the treatment of advanced non‑small cell lung cancer. Jilin Med J. 2024;45(5):1149-1152.
[8] Li L, Hu X, Cao ZG. Clinical efficacy of camrelizumab combined with chemotherapy in the treatment of elderly patients with non‑small cell lung cancer and its impact on the expression of serum CY211 and MMP‑9. J Clin Exp Med. 2023;22(22):2380-2383.
Copyright
© 2026 by the author(s).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited and is not modified or adapted.
https://creativecommons.org/licenses/by-nc-nd/4.0/
How to cite this paper
Evaluation of the Efficacy of Camrelizumab Combined with Chemotherapy in the Treatment of Lung Cancer
How to cite this paper: Haiying Fei. (2026) Evaluation of the Efficacy of Camrelizumab Combined with Chemotherapy in the Treatment of Lung Cancer. International Journal of Clinical and Experimental Medicine Research, 10(3), 233-236.
DOI: http://dx.doi.org/10.26855/ijcemr.2026.05.013